SCHEMBL8914003

SCHEMBL8914003

CC1=C(Cl)C(=O)c2ccccc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.68
DNMT1 P26358 1/20 0.68
DNMT3L Q9UJW3 1/20 0.68
DNMT3A Q9Y6K1 1/20 0.68
CDC25B P30305 4/20 0.56
CDC25A P30304 3/20 0.56
AURKA O14965 1/20 0.56
AURKB Q96GD4 1/20 0.56
RAF1 P04049 1/20 0.55
MAPK3 P27361 1/20 0.55
MAP3K8 P41279 1/20 0.55
MAP2K1 Q02750 1/20 0.55
NSD2 O96028 3/20 0.55
TDP2 O95551 2/20 0.55
PLA2G1B P04054 2/20 0.55
ATG4B Q9Y4P1 2/20 0.55
S100A4 P26447 3/20 0.52
MEN1 O00255 5/20 0.52
MAPT P10636 5/20 0.52
KMT2A Q03164 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11864498 0.83 IDO1 (0.46) IDO1DNMT1DNMT3LDNMT3ACDC25B
SCHEMBL20046946 0.83 IDO1 (0.58) IDO1DNMT1DNMT3LDNMT3ACDC25B
Dichlon SCHEMBL45723 0.82 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3ACDC25B
SCHEMBL29941466 0.82 CDC25B (0.68) IDO1DNMT1DNMT3LDNMT3ACDC25B
Dichlon SCHEMBL9751236 0.82 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3ACDC25B
SCHEMBL571026 0.82 CDC25B (0.68) IDO1DNMT1DNMT3LDNMT3ACDC25B
Dichlon SCHEMBL29360991 0.82 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3ACDC25B
SCHEMBL9627428 0.80 MEN1 (0.56) IDO1DNMT1DNMT3LDNMT3ACDC25B
Dichlon SCHEMBL10794085 0.79 IDO1 (0.94) IDO1DNMT1DNMT3LDNMT3ACDC25B
Dichlon SCHEMBL28269079 0.79 IDO1 (0.94) IDO1DNMT1DNMT3LDNMT3ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180116977-A1 NOVEL TREATMENT OF PROSTATE CARCINOMA PELLFICURE PHARMACEUTICALS, INC. 2018-05-03 US disclosed
US-9877932-B2 Treatment of prostate carcinoma PELLFICURE PHARMACEUTICALS, INC. (US) 2018-01-30 US disclosed
US-20170304288-A1 Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases TEXAS SOUTHERN UNIVERSITY (US) 2017-10-26 US disclosed
US-20170258744-A1 NOVEL TREATMENT OF PROSTATE CARCINOMA PELLFICURE PHARMACEUTICALS INC (US) 2017-09-14 US disclosed
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-20 US disclosed
US-20170071951-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases TEXAS SOUTHERN UNIVERSITY (US) 2017-03-16 US disclosed
US-20170071940-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases TEXAS SOUTHERN UNIVERSITY (US) 2017-03-16 US disclosed
US-20170071948-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases TEXAS SOUTHERN UNIVERSITY (US) 2017-03-16 US disclosed
WO-2017035501-A1 SIALYLTRANSFERASE INHIBITORS AND USES THEREOF ACADEMIA SINICA (TW) 2017-03-02 WO disclosed
WO-2017020030-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM TAIPEI MEDICAL UNIVERSITY (TW) 2017-02-02 WO disclosed
US-5091558-A Topical administeration SYNTEX (U.S.A.) INC. (US) 1992-02-25 US disclosed
US-5089657-A Topical antiinflammatory agents SYNTEX (U.S.A.) INC. (US) 1992-02-18 US disclosed
CN-1048619-A The manufacture method of direct effect grand master pattern/pressing mold that light shows DU PONT (US) 1991-01-16 CN disclosed
US-4786652-A TOPICAL ADMINISTRATION SYNTEX (U.S.A.) INC. (US) 1988-11-22 US disclosed
EP-0282006-A1 Naphtalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-09-14 EP disclosed
EP-0282056-A2 Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-09-14 EP disclosed
EP-0150831-B1 NAPHTHALENE ANTI-PSORIATIC AGENTS SYNTEX (U.S.A.) INC. (US) 1988-08-10 EP disclosed
US-4758587-A Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-07-19 US disclosed
EP-0150831-A2 Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1985-08-07 EP disclosed
US-4507241-A Method for the hydrocarbylation of naphthoquinone derivatives E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304288-A1 Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases METAP1, METAP2, DNPEP IDO1 281/4885DNMT1 2961/4885DNMT3L 3466/4885
US-20170258744-A1 NOVEL TREATMENT OF PROSTATE CARCINOMA KLK3, AR, PLK1 IDO1 3276/4885DNMT1 4547/4885DNMT3L 4526/4885
US-20180116977-A1 NOVEL TREATMENT OF PROSTATE CARCINOMA KLK3, AR, PLK1 IDO1 3276/4885DNMT1 4547/4885DNMT3L 4526/4885
US-20170071948-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases METAP1, DNPEP, METAP2 IDO1 171/4885DNMT1 1736/4885DNMT3L 3021/4885
US-20170071951-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases METAP1, DNPEP, METAP2 IDO1 171/4885DNMT1 1736/4885DNMT3L 3021/4885
US-20170071940-A1 Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases METAP1, DNPEP, METAP2 IDO1 171/4885DNMT1 1736/4885DNMT3L 3021/4885
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY USP1, USP2, USP28 IDO1 2131/4885DNMT1 290/4885DNMT3L 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.